Recapitulation of Tumor Heterogeneity and Molecular Signatures in a 3D Brain Cancer Model with Decreased Sensitivity to Histone Deacetylase Inhibition

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Smith, Stuart J ^a   Wilson, Martin ^b   Ward, Jennifer H ^a   Rahman, Cheryl V ^a   Peet, Andrew C ^b   Macarthur, Donald C ^c   Rose, Felicity R A J ^a   Grundy, Richard G ^a   Rahman, Ruman ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; MICRORNA; VORINOSTAT;

3D ROTARY CELL CULTURE SYSTEM; ARTICLE; BRAIN CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER MORPHOLOGY; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE SEQUENCE; OXYGEN TENSION; PEDIATRICS; RNA ANALYSIS; SCANNING ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; METABOLOME; PHENOTYPE; PRIMARY CELL CULTURE; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84871320580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052335     Document Type: Article

References (87)

1. Harma V, Virtanen J, Makela R, Happonen A, Mpindi J-P, et al. (2010) A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses. Plos One 5: e10431.
2. Burdett E, Kasper FK, Mikos AG, Ludwig JA, (2010) Engineering Tumors: A Tissue Engineering Perspective in Cancer Biology. Tissue Engineering Part B-Reviews 16: 351-359.
3. Kola I, Landis J, (2004) Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3: 711-715.
4. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28: 3061-3068.
5. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, et al. (2011) An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell 20: 384-399.
6. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20: 810-817.
7. Birgersdotter A, Sandberg R, Ernberg I, (2005) Gene expression perturbation in vitro- A growing case for three-dimensional (3D) culture systems. Seminars in Cancer Biology 15: 405-412.
8. Elliott NT, Yuan F, (2011) A Review of Three-Dimensional In Vitro Tissue Models for Drug Discovery and Transport Studies. Journal of Pharmaceutical Sciences 100: 59-74.
9. Weinstein JN, (2002) 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Current Opinion in Pharmacology 2: 361-365.
10. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. Journal of Clinical Investigation 119: 1727-1740.
11. Hutmacher DW, Horch RE, Loessner D, Rizzi S, Sieh S, et al. (2009) Translating tissue engineering technology platforms into cancer research. Journal of Cellular and Molecular Medicine 13: 1417-1427.
12. dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, et al. (2002) Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 19: 161-168.
13. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, et al. (2007) Engineering tumors with 3D scaffolds. Nat Methods 4: 855-860.
14. Yuhas JM, Li AP, Martinez AO, Ladman AJ, (1977) Simplified method for production and growth of multicellular tumor spheroids. Cancer Research 37: 3639-3643.
15. Acker H, Carlsson J, Muellerklieser W, Sutherland RM, (1987) Comparative pO2 measurements in cell spheroids cultured with different techniques. British Journal of Cancer 56: 325-327.
16. Bates RC, Edwards NS, Yates JD, (2000) Spheroids and cell survival. Critical Reviews in Oncology Hematology 36: 61-74.
17. Buffa FM, West C, Byrne K, Moore JV, Nahum AE, (2001) Radiation response and cure rate of human colon adenocarcinoma spheroids of different size: The significance of hypoxia on tumor control modelling. International Journal of Radiation Oncology Biology Physics 49: 1109-1118.
18. Frankel A, Buckman R, Kerbel RS, (1997) Abrogation of taxol-induced G(2)-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Research 57: 2388-2393.
19. Nicholson KM, Bibby MC, Phillips RM, (1997) Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. European Journal of Cancer 33: 1291-1298.
20. Pampaloni F, Reynaud EG, Stelzer EHK, (2007) The third dimension bridges the gap between cell culture and live tissue. Nature Reviews Molecular Cell Biology 8: 839-845.
21. Biggs T, Foreman J, Sundstrom L, Regenass U, Lehembre F, (2011) Antitumor Compound Testing in Glioblastoma Organotypic Brain Cultures. Journal of Biomolecular Screening 16: 805-817.
22. Stewart DJ, Richard MT, Benoit B, Hugenholtz H, Russell N, et al. (1984) Cisplatin plus cytosine-arabinoside in adults with malignant gliomas. Journal of Neuro-Oncology 2: 29-34.
23. Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, et al. (2008) A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). Journal of Neuro-Oncology 86: 353-358.
24. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, et al. (2012) Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. Bmc Biology 10: 29.
25. De Witt Hamer PC, Van Tilborg AAG, Eijk PP, Sminia P, Troost D, et al. (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27: 2091-2096.
26. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, et al. (2009) Genomic and Expression Profiling of Glioblastoma Stem Cell-Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival. Clinical Cancer Research 15: 6541-6550.
27. Grant DS, Kinsella JL, Fridman R, Auerbach R, Piasecki BA, et al. (1992) Interaction of endothelial-cells with a laminin-A chaine peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. Journal of Cellular Physiology 153: 614-625.
28. Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, et al. (2011) 3D Models of Epithelial-Mesenchymal Transition in Breast Cancer Metastasis: High-Throughput Screening Assay Development, Validation, and Pilot Screen. Journal of Biomolecular Screening 16: 141-154.
29. Campbell JJ, Davidenko N, Caffarel MM, Cameron RE, Watson CJ, (2011) A Multifunctional 3D Co-Culture System for Studies of Mammary Tissue Morphogenesis and Stem Cell Biology. Plos One 6: e25661.
30. Ingthorsson S, Sigurdsson V, Fridriksdottir A Jr, Jonasson JG, Kjartansson J, et al. (2010) Endothelial cells stimulate growth of normal and cancerous breast epithelial cells in 3D culture. BMC research notes 3: 184-184.
31. Hammond TG, Hammond JM, (2001) Optimized suspension culture: the rotating-wall vessel. American Journal of Physiology-Renal Physiology 281: F12-F25.
32. Schwarz RP, Goodwin TJ, Wolf DA, (1992) Cell culture for three-dimensional modeling in rotating-wall vessels: an application of simulated microgravity. J Tissue Cult Methods 14: 51-57.
33. Skardal A, Sarker SF, Crabbe A, Nickerson CA, Prestwich GD, (2010) The generation of 3-D tissue models based on hyaluronan hydrogel-coated microcarriers within a rotating wall vessel bioreactor. Biomaterials 31: 8426-8435.
34. Pellegrini M, Di Siena S, Claps G, Di Cesare S, Dolci S, et al. (2010) Microgravity promotes differentiation and meiotic entry of postnatal mouse male germ cells. PLoS One 5: e9064.
35. Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, et al. (2010) Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol 8: 791-801.
36. Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, et al. (2008) Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res 68: 9996-10003.
37. Laguinge LM, Lin S, Samara RN, Salesiotis AN, Jessup JM, (2004) Nitrosative stress in rotated three-dimensional colorectal carcinoma cell cultures induces microtubule depolymerization and apoptosis. Cancer Res 64: 2643-2648.
38. Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, et al. (2010) MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase-Mediated HOX/Stem Cell Gene Signature. Cancer Research 70: 9243-9252.
39. Bielen A, Perryman L, Box GM, Valenti M, Brandon AdH, et al. (2011) Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFR alpha/beta. Molecular Cancer Therapeutics 10: 1407-1418.
40. Phillips WT, Goins B, Bao A, Vargas D, Guttierez JE, et al. (2012) Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma. Neuro-Oncology 14: 416-425.
41. Schnell O, Romagna A, Jaehnert I, Albrecht V, Eigenbrod S, et al. (2012) Kruppel-Like Factor 8 (KLF8) Is Expressed in Gliomas of Different WHO Grades and Is Essential for Tumor Cell Proliferation. Plos One 7: e30429.
42. Rahman R, Osteso-Ibanez T, Hirst RA, Levesley J, Kilday J-P, et al. (2010) Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Molecular Cancer Therapeutics 9: 2568-2581.
43. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, et al. (2011) MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15(+)/CD133(+) Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma. Plos One 6: e24584.
44. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, et al. (2012) Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells 30: 1064-1075.
45. Fotovati A, Abu-Ali S, Wang P-S, Deleyrolle LP, Lee C, et al. (2011) YB-1 Bridges Neural Stem Cells and Brain Tumor-Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Research 71: 5569-5578.
46. Silvestrini F, Tiburcio M, Bertuccini L, Alano P, (2012) Differential Adhesive Properties of Sequestered Asexual and Sexual Stages of Plasmodium falciparum on Human Endothelial Cells Are Tissue Independent. Plos One 7: e31567.
47. Schwerk C, Papandreou T, Schuhmann D, Nickol L, Borkowski J, et al. (2012) Polar Invasion and Translocation of Neisseria meningitidis and Streptococcus suis in a Novel Human Model of the Blood-Cerebrospinal Fluid Barrier. Plos One 7: e30069.
48. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC, (2010) A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn Reson Med 65: 1-12.
49. Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, et al. (2012) CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol 124: 99-110.
50. Richon VM, O'Brien JP, (2002) Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8: 662-664.
51. Buchwald M, Kramer OH, Heinzel T, (2009) HDACi-targets beyond chromatin. Cancer Lett 280: 160-167.
52. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, et al. (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27: 2052-2058.
53. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, et al. (2010) Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 28: 3623-3629.
54. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H, (2012) The brain tumor microenvironment. Glia 60: 502-514.
55. Lathia JD, Heddleston JM, Venere M, Rich JN, (2011) Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 8: 482-485.
56. Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, et al. (2011) Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep 12: 470-476.
57. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
58. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, et al. (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10: 8177-8184.
59. Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, et al. (2011) Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res 71: 6583-6589.
60. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schaenzer A, et al. (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133: 983-995.
61. Svensson KJ, Kucharzewska P, Christianson HC, Skold S, Lofstedt T, et al. (2011) Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci U S A 108: 13147-13152.
62. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, et al. (2012) The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of Glioblastoma. Am J Pathol 180: 2108-2119.
63. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG, (2010) Hypoxia Increases the Expression of Stem-Cell Markers and Promotes Clonogenicity in Glioblastoma Neurospheres. American Journal of Pathology 177: 1491-1502.
64. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN, (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8: 3274-3284.
65. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. (2009) Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells. Cancer Cell 15: 501-513.
66. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, et al. (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97: 646-653.
67. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
68. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, et al. (2011) High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 136: 473-478.
69. Hassan SB, de la Torre M, Nygren P, Karlsson MO, Larsson R, et al. (2001) A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828. Anticancer Drugs 12: 33-42.
70. Hicks KO, Pruijn FB, Baguley BC, Wilson WR, (2001) Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J Pharmacol Exp Ther 297: 1088-1098.
71. Nyga A, Cheema U, Loizidou M, (2011) 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 5: 239-248.
72. Kim C, Bang JH, Kim YE, Lee SH, Kang JY, (2012) On-chip anticancer drug test of regular tumor spheroids formed in microwells by a distributive microchannel network. Lab on a chip 12: 4135-4142.
73. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, et al. (2010) Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 31: 8494-8506.
74. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, et al. (2007) Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res 27: 3757-3763.
75. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, et al. (2012) Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol 14: 315-325.
76. Smith BH, Gazda LS, Conn BL, Jain K, Asina S, et al. (2011) Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res 71: 716-724.
77. Davies NP, Wilson M, Natarajan K, Sun Y, MacPherson L, et al. (2010) Non-invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo 1H MRS at 1.5 tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed 23: 80-87.
78. Bibby MC, (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. European Journal of Cancer 40: 852-857.
79. Fiebig HH, Maier A, Burger AM, (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. European Journal of Cancer 40: 802-820.
80. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti J, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer 84: 1424-1431.
81. Lamfers ML, Hemminki A, (2004) Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. Current Opinion in Molecular Therapeutics 6: 403-411.
82. Suggitt M, Bibby MC, (2005) 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches. Clinical Cancer Research 11: 971-981.
83. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, et al. (2011) A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 122: 637-650.
84. Sodek KL, Ringuette MJ, Brown TJ, (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. International Journal of Cancer 124: 2060-2070.
85. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, et al. (2010) The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16: 154-163.
86. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, et al. (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 312: 1206-1212.
87. Perche F, Torchilin VP, (2012) Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biology & Therapy 13: 1205-1213.